Trial Profile
A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Seltorexant (Primary) ; Quetiapine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 01 Oct 2019 Results published in the Minerva Neurosciences Media Release
- 26 Sep 2019 According to a Minerva Neurosciences media release, the company will hold a conference call and live audio webcast on October 1, 2019, at 8:30 a.m. Eastern Time to provide updates on this study.
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.